Ibex Prostate – Precision AI for Faster, More Accurate Cancer Diagnostics
Elevate your lab’s pathology workflow with Ibex’s robust AI-powered digital assistant. Ibex Prostate empowers pathologists to diagnose with confidence, combining clinical-grade accuracy with seamless lab integration.
Why Choose Ibex Prostate?
- Accuracy: Built on a model that detects 19 tissue morphologies, it is exceptionally robust, demonstrating high performance across diverse labs, scanners, and stains.1-4 A clinical validation study demonstrated Ibex Prostate’s high accuracy in detecting cancer (AUC 0.99; specificity 97.3%; sensitivity 98.5%), Gleason pattern G5 (AUC 0.97; specificity 90.8%; sensitivity 85.0%) Gleason score G7 or above (AUC 0.94; specificity 90.4%; sensitivity 85.9%), and perineural invasion (PNI) (AUC 0.96; specificity 90.7; sensitivity 87.0%), all with 95% CI.1
- Proven Clinical Impact: In a 3-year study of 122,000 slides, Ibex identified critical findings that led to revised reports in 1.8% of cases – directly improving patient treatment plans.2
- Efficiency: Transition from 1.2 cases per hour to 2.9 cases per hour.4 Deep AI integration can significantly improve diagnostic throughput.
Core Features & Benefits
- Smart Triaging: Automatically flag and prioritize high-risk cases at the slide level.
-
- Diagnostic Safety Net: Ibex’s heatmaps pinpoint cancer, perineural invasion (PNI), inflammation, atrophy and other clinically important features, including small lesions, helping ensure nothing is missed.
- Automated Precision: Ibex AI provides suggested Gleason grading and tumor length measurements for consistent, standardized reporting.
- An Additional Set of Eyes: Gain peace of mind with an automated additional check before final sign-out.
The Ibex platform and its Prostate solution are CE-IVD certified and registered with the MHRA (UK), TGA (Australia), AMAR (Israel), and Swissmedic (Switzerland). Additional platform registrations include ANVISA (Brazil).
United States: Includes one FDA-cleared solution; all others are Research Use Only (RUO).
Ibex Prostate for TURP: Designated as RUO globally.
For specific intended use and full regulatory details, please contact Ibex Medical Analytics.
References
[1] Pantanowitz et al. Lancet Digital Health (2020) 2(8): e407-e416.
[2] Santa-Rosario et al. Journal of Pathology Informatics (2024), 15:100378.
[3] Lami et al. Pathology (2024), 56; 5:633-642
[4] Borkowski et al. Quest Diagnostics, Proscia, Ibex 2024.
